Correlation of Audiovisual Features With Clinical Variables and Neurocognitive Functions in Bipolar Disorder, Mania

February 25, 2019 updated by: Elvan Çiftçi, Istanbul Saglik Bilimleri University
The aim of this study is to show the physiological changes during manic episode in bipolar mania how much they differentiate from remission and healthy control. Relation of audio-visual features as physiological changes and cognitive functions and clinical variables will be searched. The aim is to find biologic markers for predictors of treatment response via machine learning techniques to be able to reduce treatment resistance and give an idea for personalized treatment of bipolar patients.

Study Overview

Detailed Description

The objective of this research protocol is to find audio-visual features which differentiates bipolar mani/ remission/ health/ simulation and predicts treatment response earlier and detect neurocognitive changes during mania/ remission and difference from the healthy control. During hospitalization in every follow up day (0th- 3rd- 7th- 14th- 28th day) and after discharge on the 3rd month, presence of depressive and manic features for patients was evaluated using Young Mania Rating Scale(YMRS) and Montgamery- Asberg Depresyon Scale (MADRS). Audiovisual recording is done by a video camera in every follow up day for patients and for healthy controls which includes also depression and mania simulation. Cambridge Neurophysiological Assessment Battery (CANTAB) were administered to both groups( for patients both in the manic phase and in the remission) to assess neurocognitive functions.

Study Type

Observational

Enrollment (Actual)

89

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34736
        • SBU Erenkoy Mental State Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Bipolar mania patients from the inpatient service Healthy controls from the community around hospital

Description

Inclusion Criteria:

  • diagnosis of BD type I, manic episode according to DSM-5 [10] given by the following doctor,
  • being informed of the purpose of the study and having given signed consent before enrollment.

Exclusion Criteria:

  • being younger than 18 years or older than 60 years,
  • showing low mental capacity during the interview
  • expression of hallucinations and disruptive behaviors during the interview,
  • presence of severe organic disease,
  • presence of any organic disease that may affect cognition
  • having less than five years of public education
  • diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine)
  • presence of cerebrovascular disorder, head trauma with longer duration of loss of consciousness, severe hemorrhage and dementia,
  • having electroconvulsive therapy in the last one year.

For the healthy control group, the following additional criteria were considered for exclusion

  • presence of family history of mood or psychotic disorder,
  • presence of psychiatric disorder during interview or in the past.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Bipolar Mania
Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
Prescribed by the following doctor during hospitalization and after discharge
Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
Healthy Control
showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment response
Time Frame: from baseline until 3rd month

The proportion of Young Mania Rating Scale(YMRS) score ( at baseline to 3rd- 7th- 14th- 28th day and 3rd month ( Baseline scale/ Follow-up day scale) YMRS score utilized rating scales to assess manic symptoms ranged between 0-76

  1. Remission: Yt <= 7
  2. Hypomania: 7 < Yt < 20
  3. Mania: Yt >= 20.
from baseline until 3rd month
Changes in visual features
Time Frame: Baseline and 3rd month

Functionals of appearance descriptors extracted from fine-tuned Deep Convolutional Neural Networks (DCNN), geometric features obtained using tracked facial landmarks (Unweighted Average Recall)

Geometric frame level 23 geometric features and apperance descriptors 4096 dimensional features from the last convolutional layer of the FER fine-tuned CNN which are summarized via mean and range functionals over sub-clips and the decisions are voted at video level, an UAR performance is obtained.

Feature vectors extracted from video is modelled using Partial Least Squares (PLS) regression and Extreme Learning Machines classifiers

Unweighted Average Recall (UAR), which is mean of class-wise recall scores, is commonly used as performance measure, instead of accuracy, which can be misleading in the case of class-imbalance

Baseline and 3rd month
Changes in audio features
Time Frame: Baseline and 3rd month

Functionals of acoustic features extracted via openSMILE tool (Unweighted Average Recall)

Acoustic low level descriptors including prosody (energy, Fundamental Frequency - F0), voice quality features (jitter and shimmer), Mel Frequency Cepstral Coefficients, which are commonly used in many speech technologies from audio, we use the 76-dimensional standard feature set used in the INTERSPEECH 2010 paralinguistic challenge as baseline.

The second is our proposed set of 10 functionals, Mean, standard deviation, curvature coefficient , slope and offset , minimum value and its relative position, maximum value and its relative position, and the range

Feature vectors extracted from audio is modelled using Partial Least Squares (PLS) regression and Extreme Learning Machines classifiers.

Baseline and 3rd month
in Stop Signal Test
Time Frame: Baseline and 3rd month
(milisecond) SST- Succesful Stop Ratio SST- go- Reaction Time SST- Stop Signal Delay SST- Stop Signal Reaction Time SST- Total Correct
Baseline and 3rd month
Changes in Rapid Visual Processing
Time Frame: Baseline and 3rd month

RVP A' (A prime) is the signal detection measure of sensitivity to the target, regardless of response tendency (range 0.00 to 1.00; bad to good).

RVP B'' (B double prime) is the signal detection measure of the strength of trace required to elicit a response (range -1.00 to +1.00)

Baseline and 3rd month
in Cambridge Gambling Task
Time Frame: Baseline and 3rd month
(milisecond) CGT Quality of decision making CGT Deliberation time CGT Delay aversion CGT Overall proportion bet
Baseline and 3rd month
Changes in Emotion Recognition Test
Time Frame: Baseline and 3rd month
(rate of emotion prediction) Percent and numbers correct/incorrect prediction
Baseline and 3rd month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Heysem Kaya, Ass Prof, Namik Kemal University
  • Study Chair: Ali A Salah, Ass Prof, Bogazici University
  • Study Chair: Hüseyin Gülec, Ass Prof, İstanbul Sağlık Bilimleri University
  • Principal Investigator: Elvan Ciftci, MD PhD, İstanbul Sağlık Bilimleri University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Ciftci E, Kaya H, Gulec H, Salah AA (2018) The Turkish Audio-Visual Bipolar Disorder Corpus. In: 2018 First Asian Conference on Affective Computing and Intelligent Interaction (ACII Asia), pp 1-6. IEEE. Available at: https://ieeexplore.ieee.org/document/8470362/
  • Çiftçi E, Kaya H, Güleç H and Salah AA Potential audio treatment predictors for bipolar mania Psychiatry and Clinical Psychopharmacology Supplementary

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 30, 2016

Primary Completion (ACTUAL)

February 20, 2017

Study Completion (ACTUAL)

July 8, 2017

Study Registration Dates

First Submitted

April 15, 2018

First Submitted That Met QC Criteria

February 25, 2019

First Posted (ACTUAL)

February 28, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 28, 2019

Last Update Submitted That Met QC Criteria

February 25, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The database will be introduced in AVEC 2018 competition and shared with participants. After the competition the databese will be shared under the special EULA permission.

IPD Sharing Time Frame

5 years

IPD Sharing Access Criteria

EULA permission

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Artificial Intelligence

Clinical Trials on Ongoing treatment for bipolar mania

Subscribe